Radiologic criteria of response to systemic treatments for hepatocellular carcinoma.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2017-10-01 Epub Date: 2017-11-17 DOI:10.2217/hep-2017-0018

Francesco Tovoli, Matteo Renzulli, Alessandro Granito, Rita Golfieri, Luigi Bolondi

引用次数: 17

Abstract

Sorafenib has been the only approved systemic therapy for hepatocellular carcinoma until very recently. However, the radiologic assessment of its biological activity is a disputed matter as at least five different criteria have been proposed. In this review, we describe the characteristic of the Response Evaluation Criteria In Solid Tumors (RECIST), European Association for the Study of The Liver (EASL), modified RECIST (mRECIST), Response Evaluation Criteria In the Cancer of the Liver (RECICL) and Choi criteria. The existing comparative studies are reported together with recent pieces of evidence, analyzing the reasons behind the split between recommendations of the scientific societies and regulatory agencies. Future perspectives in the wake of the impending results of the immunotherapy trials are also discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝细胞癌全身治疗反应的放射学标准。

直到最近，索拉非尼一直是唯一被批准用于肝细胞癌的全身疗法。然而，其生物活性的放射学评估是一个有争议的问题，因为至少有五种不同的标准被提出。在这篇综述中，我们描述了实体肿瘤反应评价标准(RECIST)、欧洲肝脏研究协会(EASL)、修订后的RECIST (mRECIST)、肝癌反应评价标准(RECICL)和Choi标准的特点。现有的比较研究与最近的证据一起报告，分析了科学协会和监管机构的建议之间分歧的原因。在即将到来的免疫治疗试验的结果之后，未来的观点也进行了讨论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.